Enliven Therapeutics, Inc.
Financials
Valuation Metrics
Enliven Therapeutics, Inc.'s Market Cap is $3.27B. At end of 2025 it was $873M. Ranked #1639 of 3,116 in US market (top 53%), #576 of 1,472 on NASDAQ (top 39%), #96 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 36%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.27B | US#1,639/3,116 Sec#96/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-106M | US—/3,116 Sec—/265 |
| Total Assets | $910M | US#2,514/3,116 Sec#109/265 |
| Net Assets | $895M | US#1,837/3,116 Sec#74/265 |
| Employees | 67 | US#2,665/3,116 Sec#196/265 |
| Value | ||
| P/B | 3.65x | US#1,967/3,116 Sec#116/265 |
| FCF Yield | -2.05% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -11.83% | US#2,386/3,116 Sec#84/265 |
| ROA | -11.64% | US#2,683/3,116 Sec#106/265 |
| Financial Health | ||
| Debt Ratio | 1.68% | US#14/3,116 Sec#3/265 |
| Total Debt | $2M | US#2,952/3,116 Sec#236/265 |
| FCF | $-67M | US#2,566/3,116 Sec#122/265 |
| Cash | $136M | US#2,018/3,116 Sec#144/265 |
| Current Ratio | 64.07x | US#47/3,116 Sec#4/265 |
| Performance | ||
| 1Y Return | 90.52% | US#166/3,116 Sec#43/265 |
| 1M Return | -5.00% | US#2,151/3,116 Sec#147/265 |
| From 52W High | -28.40% | US#1,898/3,116 Sec#122/265 |
| 1Y MDD | -38.97% | US#1,885/3,116 Sec#111/265 |
| Trading | ||
| Volume | 720,282 shares | US#1,836/3,116 Sec#182/265 |
| Trading Value | $32M | US#1,649/3,116 Sec#122/265 |
| Per Share | ||
| EPS | $-1.45 | US—/3,116 Sec—/265 |
| BPS | $12.22 | US#1,687/3,116 Sec#60/265 |
Company Info
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.